Lupin has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug Administration (USFDA) to market a generic version of Novartis Pharmaceuticals Corporation’s TOBI 300 mg/5 ml.
Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the AN rated generic equivalent of Novartis Pharmaceuticals Corporation’s TOBI 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa. Tobramycin Inhalation Solution USP, 300 mg/5 ml had US sales of $133.6 million as per IMS MAT December 2016.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
